Vietnam's pharmaceutical drug delivery market is set for sustained growth as the country expands access to advanced medicines, strengthens domestic pharmaceutical manufacturing and invests in innovative drug delivery technologies that improve patient outcomes.
According to IMARC Group, Vietnam's pharmaceutical drug delivery market reached US$7.7 billion in 2025 and is projected to grow to US$12.2 billion by 2034. Growth is being driven by an ageing population, rising rates of chronic disease, increasing healthcare expenditure and growing demand for more effective, patient-centric drug delivery systems.
The pharmaceutical drug delivery sector forms a vital component of Vietnam's rapidly expanding pharmaceutical industry. The country's overall pharmaceutical market was valued at US$8.0 billion in 2025 and is forecast to reach US$14.6 billion by 2034. Increasing government investment in healthcare, broader insurance coverage and rising demand for innovative therapies continue to create opportunities across the pharmaceutical value chain.
Several structural trends are accelerating demand for advanced drug delivery technologies across Vietnam:
- Rising prevalence of cancer, diabetes, cardiovascular disease and other chronic conditions requiring long-term treatment.
- Rapid growth in biologics, biosimilars and specialty medicines that rely on sophisticated delivery platforms.
- Expansion of domestic pharmaceutical manufacturing and contract manufacturing capabilities.
- Increasing demand for self-administered therapies and home healthcare.
- Greater adoption of sustained-release, controlled-release and targeted drug delivery systems.
- Advances in nanotechnology, smart drug delivery devices and precision medicine.
Modern drug delivery technologies are transforming patient care by improving the way medicines are administered and absorbed. Innovations such as prefilled syringes, autoinjectors, wearable injectors, implantable delivery systems and nanoparticle-based formulations are enhancing treatment effectiveness, reducing side effects and improving patient adherence. These technologies are becoming increasingly important for high-growth therapeutic areas including oncology, diabetes, autoimmune diseases and rare diseases.
Vietnam's growth also reflects wider regional momentum. Across Southeast Asia, the pharmaceutical drug delivery market reached US$30.1 billion in 2025 and is projected to expand to US$57.4 billion by 2034, highlighting the region's growing importance for pharmaceutical innovation and advanced therapeutics.
Leading global pharmaceutical companies including Pfizer, Roche, Novartis, Sanofi, AstraZeneca, Novo Nordisk and Johnson & Johnson, together with specialist drug delivery technology providers such as West Pharmaceutical Services, Gerresheimer, SCHOTT Pharma, Catalent and Becton Dickinson (BD), continue to invest in next-generation delivery platforms that improve therapeutic performance and patient convenience.
As Vietnam continues to modernise its healthcare system and strengthen its pharmaceutical manufacturing base, advanced drug delivery technologies are expected to play an increasingly important role in supporting biologics, precision medicine and next-generation therapeutics. For suppliers of drug delivery devices, injectable technologies, pharmaceutical packaging, manufacturing equipment and contract development services, Vietnam represents one of Southeast Asia's most attractive long-term growth markets.
